Achieving price solutions for combination regimens that are mutually acceptable to both industry and payers in global healthcare systems, is a challenge that shows little sign of being solved. Although solutions have been suggested, successful implementation remains problematic.
The upcoming LoE of Keytruda (pembrolizumab) is expected to bring about significant changes in the oncology landscape with the influx of biosimilars. For some, LoE is viewed as a potential solution to the combination pricing challenge. In this article, CRA’s Aaron Everitt examines how Keytruda LoE might impact: 1) affordability, 2) clinical comparator choice, and 3) price comparator choice.
Read more about Keytruda LoE and the combination pricing problem
